A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3828136 in Healthy Participants
Latest Information Update: 21 Oct 2024
At a glance
- Drugs CK 136 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Cytokinetics
Most Recent Events
- 15 Oct 2024 According to ClinicalTrials.gov record this trial is Terminated early as per sponsor decision.
- 15 Oct 2024 Status changed from recruiting to discontinued.
- 27 Feb 2024 According to a Cytokinetics media release, the study has proceeded to multiple ascending dose (MAD) cohorts of the Phase 1 study. The company expect to complete Phase 1 study of CK-136 in Q2 2024.